Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment: ALBUMINATED PLGA NANOPARTICLES FOR OCULAR NEOVASCULARIZATION TREATMENT
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Bevacizumab, an anti-VEGF antibody, has demonstrated trustworthy effects in treatment of retinal and choroidal neovascularization that both are crucial sight threatening conditions. However, the weak point is the short half-life of the drug in vitreous which necessitates frequent intravitreal injections. Accordingly employing controlled-release drug delivery systems such as polymeric nanoparticles (NPs) has been suggested. In this study albuminated-PLGA-NPs containing bevacizumab were prepared and studied intended for reducing the number of injections. NPs were formulated by double-emulsion method and a single dose of NPs was intravitreally injected to rabbits. The drug concentrations in vitreous and aqueous humor were assayed in different time intervals using ELISA and intraocular pharmacokinetic parameters were calculated. Moreover, coumarin-6 loaded albuminated-PLGA-NPs were employed to evaluate the distribution and persistence of the NPs in the posterior segment. Results revealed that the bevacizumab vitreous concentration maintained above 500 ng mL(-1) for about 8 weeks and 3.3 times elevation was observed in the drug vitreous MRT compared with the control. According to coumarin-6 NP tests, fluorescence emissions in posterior tissues were observed for 56 days which confirmed the nanoparticles persistence in ocular tissues during the test span. Therefore our prepared formulation may offer improvements in treatment of eye posterior segment neovascularization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Molecular pathology of age-related macular degeneration
Ding, X., Patel, M., & Chan, C.-C. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.10.001 · Cited by 582
In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems
Semete, B., Booysen, L., Lemmer, Y., Kalombo, L., Katata, L., Verschoor, J., & Swai, H. S. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2010.02.002 · Cited by 425
Shienbaum, G., Gupta, O. P., Fecarotta, C., Patel, A. H., Kaiser, R. S., & Regillo, C. D. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.011 · Cited by 77
Cited by
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s383101 · Cited by 111
Nanoparticulate drug delivery to the retina
Li, Q., Weng, J., Wong, S. N., Thomas Lee, W. Y., & Chow, S. F. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00224 · Cited by 59
Xu, J.-F., Wang, Y.-P., & Liu, X.-H. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.06.019 · Cited by 12
Metadata
- Authors
- Varshochian, R., Riazi-Esfahani, M., Jeddi-Tehrani, M., Mahmoudi, A.-R., Aghazadeh, S., Mahbod, M., Movassat, M., Atyabi, F., Sabzevari, A., & Dinarvand, R.
- Venue
- Journal of Biomedical Materials Research Part A
- Publisher
- Wiley
- Published
- 2015-03-27
- Volume
- 103
- Issue
- 10
- Pages
- 3148-3156
- ISSN
- 1549-3296 (ISSN-L)
- OpenAlex
- W2140848006
- Cited by
- 114
- References
- 4
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.